- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ENTERING INTO OF THE LICENSE AGREEMENT | 2 | HKEx | ||
| 16.11. | Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab | 406 | GlobeNewswire (Europe) | SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 15.11. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL BY THE MHRA FOR MARKETING OF TORIPALIMAB | - | HKEx | ||
| 12.11. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE COMPLETION OF THE PLAN FOR THE REDUCTION ... | - | HKEx | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* INDICATIVE ANNOUNCEMENT ON THE CHANGES IN EQUITY OF THE ... | 11 | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2024 THIRD QUARTERLY ... | 1 | HKEx | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON CHANGING THE IMPLEMENTATION ENTITY FOR INVESTMENT ... | 1 | HKEx | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON UTILIZING THE REMAINING SURPLUS PROCEEDS ... | - | HKEx | ||
| 29.10. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2024 THIRD QUARTERLY REPORT | - | HKEx | ||
| 23.10. | JUNSHI BIO (01877): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 23.10. | JUNSHI BIO (01877): PASSING AWAY OF INDEPENDENT NON-EXECUTIVE DIRECTOR DR. SHEN JINGKANG | 3 | HKEx | ||
| 17.10. | JUNSHI BIO (01877): DATE OF BOARD MEETING | 1 | HKEx | ||
| 15.10. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF TORIPALIMAB IN HONG KONG SAR, CHINA | - | HKEx | ||
| 15.10. | Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China's Hong Kong SAR | 191 | GlobeNewswire (Europe) | SHANGHAI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 27.09. | JUNSHI BIO (01877): 2024 INTERIM REPORT | - | HKEx | ||
| 26.09. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE LICENSE AND COOPERATION AGREEMENT BETWEEN SUBSIDIARY AND JSIAMA | 1 | HKEx | ||
| 26.09. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - JS125 RECEIVED THE NOTICE OF APPROVAL FOR CLINICAL TRIAL | - | HKEx | ||
| 26.09. | JUNSHI BIO (01877): SUPPLEMENTAL ANNOUNCEMENT - CONNECTED TRANSACTIONS IN RELATION TO THE ENTERING INTO OF THE REORGANIZATION FRAMEWORK AGREEMENT | - | HKEx | ||
| 25.09. | Junshi Bio Surges in Hong Kong After EU Approves Its Cancer Drug for Sales | 2 | Yicai Global | ||
| 25.09. | Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab | 335 | GlobeNewswire (Europe) | SHANGHAI, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen |
Seite:
1 2 3 4 Weiter >>
68 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,500 | -15,59 % | Evotec: Jetzt ist hier wieder richtig Pfeffer drin | Es ist ein Klassiker: Ein vorher vielversprechendes Unternehmen strauchelt, der Aktienkurs bricht ein - und dadurch wird das Unternehmen zu einem lukrativen Ziel für Konkurrenten und Großinvestoren.... ► Artikel lesen | |
| QIAGEN | 41,045 | +2,05 % | Qiagen NV-Aktie büßt 0,31 Prozent ein (39,06 €) | Im Minus liegt zur Stunde der Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 39,06 Euro. An der Börse liegt die Qiagen NV-Aktie aktuell im Minus. Das Papier verbilligte sich um 12 Cent. Das Wertpapier... ► Artikel lesen | |
| ARCELLX | 90,44 | +3,69 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| BIONTECH | 108,90 | +0,28 % | Märkte am Morgen: Amazon, Samsung Electronics, BioNTech, Netflix, Tesla | Der DAX hat eine Woche voller Schwankungen hinter sich. Am Freitag verabschiedete er sich mit einem kleinen Minus ins Wochenende. Die Vorgaben aus Übersee sind diesmal durchwachsen. Trotzdem deutet... ► Artikel lesen | |
| DYNE THERAPEUTICS | 29,690 | -0,27 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| KYMERA THERAPEUTICS | 44,980 | +3,38 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update | KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| KEROS THERAPEUTICS | 55,92 | +3,86 % | Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | ||
| MODERNA | 39,575 | +0,18 % | Opening Bell: Bitcoin, Tesla, Moderna, Netflix, Palantir, Nvidia | Vor dem Wochenende ging es für den Dow Jones um 0,7 Prozent abwärts. Auch auf Wochensicht fuhr er Verluste ein, hier gab er 1,3 Prozent ab. Der Nasdaq 100 verlor sogar 2,4 Prozent in der vergangenen... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,79 | +0,01 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,290 | +2,68 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
| SPRINGWORKS THERAPEUTICS | 39,030 | +7,52 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 7,790 | -2,50 % | 4D Molecular initiated by Morgan Stanley at underweight | ||
| RELAY THERAPEUTICS | 4,750 | +2,37 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights | Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of... ► Artikel lesen |
Das Unternehmen SHANGHAI JUNSHI BIOSCIENCES CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -3,97 % bei einem Aktienkurs von 1,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.
